lactulose

Brand: Kristalose, Enulose

Prototype Drug
Drug Class: laxative (osmotic) / hyperammonemia treatment
Drug Family: GI agent
Subclass: disaccharide osmotic agent
Organ Systems: gastrointestinal

Mechanism of Action

Non-absorbable disaccharide metabolized by colonic bacteria to lactic and acetic acid; osmotic effect draws water into lumen; acidification of colon traps ammonium (NH4+) reducing absorption in hepatic encephalopathy.

colonic bacteria (metabolizes to organic acids)

Indications

  • constipation (chronic)
  • hepatic encephalopathy (prevention and treatment)
  • portal systemic encephalopathy

Contraindications

  • galactosemia
  • bowel obstruction

Adverse Effects

Common

  • flatulence
  • bloating
  • cramping
  • diarrhea

Serious

  • severe electrolyte disturbances (overdose)
  • aspiration risk

Pharmacokinetics (ADME)

Absorption minimal absorption
Distribution colonic lumen
Metabolism colonic bacteria to lactate, acetate, formate
Excretion fecal
Half-life not applicable
Onset 24-48 hours (constipation)
Peak 24-48 hours
Duration variable
Protein Binding none
Vd none

Nursing Considerations

  1. Hepatic encephalopathy: titrate dose to 2-3 soft stools per day
  2. Lactulose enema: 300 mL in 700 mL water for acute hepatic encephalopathy if oral not possible
  3. Monitor for electrolyte disturbances with high doses
  4. Can mix with juice or water to improve taste (sweet syrup)

Clinical Pearls

  • Dual mechanism in hepatic encephalopathy: osmotic laxative reduces gut transit + acidification traps NH3 as NH4+ reducing absorption
  • Titrate to 2-3 stools/day — too few bowel movements means under-treated, too many risks dehydration

Safety Profile

Pregnancy safe
Lactation generally-safe
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.